(Q85225899)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Mathias Warm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ronald Kates

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Friedrich Overkamp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Anke Thomas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Nadia Harbeck

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20960229

6 August 2024

publication date

20 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

15 February 2020

https://hal.archives-ouvertes.fr/hal-00587266/file/PEER_stage2_10.1007%252Fs10549-010-1214-3.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20960229

http://link.springer.com/content/pdf/10.1007/s10549-010-1214-3.pdf

6 August 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

http://link.springer.com/article/10.1007/s10549-010-1214-3/fulltext.html

6 August 2024

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

http://link.springer.com/content/pdf/10.1007/s10549-010-1214-3

6 August 2024

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Breast Cancer Research and Treatment

6 August 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

127-136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20960229%20AND%20SRC:MED&resulttype=core&format=json

What clinicians need to know about antioestrogen resistance in breast cancer therapy

15 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients

6 August 2024

2

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

The future of fulvestrant ("Faslodex").

6 August 2024

4

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

6 August 2024

6

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

6 August 2024

7

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling

6 August 2024

8

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.

6 August 2024

9

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer

6 August 2024

10

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

6 August 2024

12

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

6 August 2024

13

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

6 August 2024

14

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

6 August 2024

15

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

6 August 2024

16

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

6 August 2024

17

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

6 August 2024

18

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene

6 August 2024

19

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.

6 August 2024

20

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Time to response: comparison of fulvestrant and oral endocrine agents.

6 August 2024

22

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

6 August 2024

23

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

6 August 2024

24

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme

6 August 2024

25

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial

6 August 2024

26

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer

6 August 2024

27

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Repeated observation of breast tumor subtypes in independent gene expression data sets

6 August 2024

28

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model

6 August 2024

29

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.

6 August 2024

30

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Prolonged time to progression with fulvestrant for metastatic breast cancer

6 August 2024

31

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

6 August 2024

32

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

6 August 2024

33

1 reference

https://api.crossref.org/works/10.1007/S10549-010-1214-3